Co-Authors
This is a "connection" page, showing publications co-authored by Alexander Pearson and Dezheng Huo.
Connection Strength
1.450
-
Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer. medRxiv. 2026 May 05.
Score: 0.243
-
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer. medRxiv. 2025 Aug 27.
Score: 0.232
-
External Evaluation of a Mammography-based Deep Learning Model for Predicting Breast Cancer in an Ethnically Diverse Population. Radiol Artif Intell. 2023 Nov; 5(6):e220299.
Score: 0.200
-
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. NPJ Breast Cancer. 2023 Apr 14; 9(1):25.
Score: 0.197
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.174
-
Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Glob Oncol. 2026 May; 12(5):e2500705.
Score: 0.061
-
Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence. medRxiv. 2026 May 12.
Score: 0.061
-
Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide images. NPJ Breast Cancer. 2026 May 11; 12(1).
Score: 0.061
-
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study. Lancet Oncol. 2026 Apr; 27(4):512-526.
Score: 0.060
-
Deep Learning on Histopathological Images to Predict Breast Cancer Recurrence Risk and Chemotherapy Benefit. medRxiv. 2025 May 16.
Score: 0.057
-
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence. NPJ Breast Cancer. 2024 Jun 15; 10(1):46.
Score: 0.053
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 04 15; 130(8):1210-1220.
Score: 0.052